One of Britain’s most promising biotechnology companies is preparing to launch an initial public offering in the coming weeks.
Oxford Nanopore, a gene sequencing company, is working with banks on a float on the London Stock Exchange and is targeting a valuation above the £2.5 billion it was valued at during a fundraising in May.
The potential listing is a boost for the London market because biotech companies often look to the Nasdaq in New York to attract higher valuations.
Oxford Nanopore said in March that it was preparing for a float and expected to list in the
Read more here: Source link